高病毒载量且ALT未显著升高的未治疗HBeAg阴性慢性乙肝患者临床事件风险高
该历史队列纳入2000至2013年韩国一家三级医院的5414例无肝硬化HBeAg阴性慢性乙肝患者,比较未治疗的高病毒载量且ALT正常或轻度升高者与因ALT≥2倍正常上限而治疗的活跃期患者的临床结局。倾向评分匹配分析显示,未治疗的复制期患者肝细胞癌(HR 1.76;95%CI 1.00-3.10,P=0.05)和死亡/移植(HR 2.14;95%CI 1.09-4.21,P=0.03)风险显著高于治疗的活跃期组。
要点
- 未治疗的高病毒载量且ALT持续正常患者,肝细胞癌风险高于治疗的活跃期患者(HR 1.76)。
- 未治疗的高病毒载量且ALT持续正常患者,死亡/移植风险高于治疗的活跃期患者(HR 2.14)。
- 未治疗的轻度活跃期患者较治疗的活跃期患者肝细胞癌和死亡/移植风险进一步增加。
核心结论
- 未治疗的高病毒载量HBeAg阴性慢性乙肝患者,即使ALT未显著升高,其临床事件风险仍高于因ALT≥2倍正常上限而治疗的活跃期患者。
研究设计与样本
- 历史队列研究,纳入2000至2013年韩国一家三级医院5414例无肝硬化HBeAg阴性慢性乙肝患者。
- 非活跃期定义为血清HBV DNA<2000 IU/mL且ALT持续正常(n=3572)。
- 高病毒载量(HBV DNA≥2000 IU/mL)患者按ALT水平分为三组:复制期(ALT持续正常,n=900)、轻度活跃期(ALT 1-2倍正常上限,n=396)和活跃期(ALT≥2倍正常上限,n=546)。
- 所有活跃期患者均接受核苷(酸)类似物治疗。
主要发现
- 患者平均年龄47岁,各组间无显著差异。
- 倾向评分匹配分析显示,与治疗的活跃期组相比,未治疗的复制期组肝细胞癌风险显著更高(HR 1.76;95%CI 1.00-3.10,P=0.05)。
- 倾向评分匹配分析显示,与治疗的活跃期组相比,未治疗的复制期组死亡/移植风险显著更高(HR 2.14;95%CI 1.09-4.21,P=0.03)。
- 未调整、倾向评分匹配、竞争风险和 multivariable 调整分析均显示,未治疗的轻度活跃期患者较治疗的活跃期组肝细胞癌和死亡/移植风险进一步增加。
关键数值与推荐
- 非活跃期:HBV DNA<2000 IU/mL且ALT持续正常。
- 高病毒载量:HBV DNA≥2000 IU/mL。
- 复制期:ALT持续正常;轻度活跃期:ALT 1-2倍正常上限;活跃期:ALT≥2倍正常上限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unknown whether antiviral treatment for HBeAg-negative chronic hepatitis B (CHB) patients having high viral loads without significant elevation of alanine aminotransferase (ALT) levels would reduce the risks of clinical events. AIM: To compare clinical outcomes of high viral load CHB patients untreated for normal or mildly elevated ALT vs those treated for ALT ≥ 2 upper limit of normal (ULN). METHODS: This historical cohort study included 5414 HBeAg-negative CHB patients without cirrhosis at a tertiary hospital in Korea from 2000 to 2013. Inactive phase was defined as serum hepatitis B virus [HBV] DNA < 2000 IU/mL and persistently normal ALT (n = 3572). High viral load (HBV DNA ≥ 2000 IU/mL) patients were classified into three phases by ALT levels: Replicative (persistently normal ALT, n = 900); Mildly active (ALT 1-2ULN, n = 396); and Active (ALT ≥ 2ULN, n = 546) phases. All Active phase patients were treated with nucleos(t)ide analogues. RESULTS: The mean age of the patients was 47 years without a significant difference among the groups. Compared with the treated Active phase group, the untreated Replicative phase group showed a significantly higher risk of hepatocellular carcinoma (HCC; HR 1.76; 95% CI 1.00 - 3.10, P = 0.05) and death/transplantation (HR 2.14; 5% CI 1.09 - 4.21, P = 0.03) by propensity score-matched analysis. The untreated mildly active phase patients had further increase in risk of HCC and death/transplantation compared with the treated Active phase group by unadjusted, PS-matched, competing risks, and multivariable-adjusted analyses. CONCLUSIONS: Untreated high viral load HBeAg-negative CHB patients without significant ALT elevation had higher risks of clinical events than treated Active phase patients with elevated ALT.
引用
- Choi GH, Kim GA, Choi J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther. 2019. PMID: 31135074. doi:10.1111/apt.15311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。